Virginia Senate Bill SB621

Virginia 2022 Regular Session

• Introduced: 1/14/22
• Refer: 1/14/22

Caption

Cannabis products; retail sales by certain pharmaceutical processors.

Impact

Implementation of SB621 will significantly alter Virginia's cannabis landscape by expanding legal sale channels through pharmaceutical processors. A 21 percent excise tax will be applied to sales, which is designed to generate revenue for the state’s general fund and support independent cannabis retailers in underserved areas. This tax revenue model aligns with broader fiscal strategies to capitalize on the cannabis market while also aiming to promote economic equity by providing assistance to retailers in both urban and rural opportunity zones.

Summary

SB621 introduces a regulatory framework for the retail sale of cannabis products by certified pharmaceutical processors in Virginia. Specifically, the bill allows these processors to sell cannabis products directly to consumers aged 21 and older without the need for a written certification, moving away from stricter regulations previously in place. This shift aims to facilitate easier access to cannabis products while ensuring consumer protections are in place through existing pharmaceutical regulations. The bill requires that all sales adhere to specific packaging and reporting guidelines to aid in consumer safety and compliance monitoring.

Contention

While supporters argue that SB621 represents a progressive step towards cannabis accessibility and economic growth, critics express concerns regarding potential overreach or insufficient regulatory oversight. Key points of contention include the implications of reducing barriers for sales and whether this could lead to increased usage among young people, despite restrictions on advertising cannabis products to minors. Additionally, the bill's focus on civil liability protections for pharmaceutical processors raises questions regarding accountability and consumer protections in the event of product issues or malpractices.